Anaesthetic firm seeks operating partner.
Maelor chief executive Stephen Appelbee said: ``We are equally delighted with the pre-clinical work, which for the first time demonstrates the potential utility of micelle propofol in the maintenance of sedation. We can now offer to potential partners a formulation which can meet or exceed all the current therapeutic benchmarks.''
|Printer friendly Cite/link Email Feedback|
|Publication:||Daily Post (Liverpool, England)|
|Date:||Jan 7, 2003|
|Previous Article:||OBSERVATORY TO BE SHOWCASE FOR LIVERPOOL VISION.|
|Next Article:||Thunderbirds are go - not to mention Sindy; MANAGEMENT BUY TOYMAKER IN pounds 62m DEAL.|